Raymond James Financial
INDV icon

Raymond James Financial’s Indivior Pharmaceuticals INDV Stock Holding History

Raymond James Financial’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$685K Sell
22,478
-38,347
-63% -$1.27M ﹤0.01% 4127
2025
Q4 		$2.18M Buy
60,825
+12,053
+25% +$368K ﹤0.01% 3210
2025
Q3 		$1.18M Buy
48,772
+47,037
+2,711% +$984K ﹤0.01% 3579
2025
Q2 		$25.6K Buy
+1,735
New +$20.2K ﹤0.01% 5489

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's INDV Position: Q1 2026 in Review

Raymond James Financial reduced its Indivior Pharmaceuticals (INDV) stake by 63% in Q1 2026, selling an estimated $1.27M and leaving 22,478 shares worth $685K. The position accounts for ﹤0.01% of the portfolio, ranked #4127.

Raymond James Financial first reported a position in INDV in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.18M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Raymond James Financial held 22,478 shares of Indivior Pharmaceuticals worth $685K as of Q1 2026.
  • Raymond James Financial sold 38,347 Indivior Pharmaceuticals shares in Q1 2026, an estimated $1.27M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4127 holding.
  • Raymond James Financial first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Indivior Pharmaceuticals position peaked at $2.18M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.